Complement C5 Inhibitor [EPC]

121 reported adverse events

Drugs of this class: CROVALIMAB

These side effects are most commonly reported by patients taking drugs of the Complement C5 Inhibitor [EPC] class:

# Side effect Count
0 PYREXIA 21
1 TYPE III IMMUNE COMPLEX MEDIATED REACTION 21
2 ANAEMIA 20
3 OFF LABEL USE 15
4 HAEMOLYSIS 14
5 INFECTION 11
6 BREAKTHROUGH HAEMOLYSIS 10
7 PNEUMONIA 10
8 HEPATIC FUNCTION ABNORMAL 8
9 COVID-19 7
See all common reactions for Complement C5 Inhibitor [EPC]

Drugs of the Complement C5 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TYPE III IMMUNE COMPLEX MEDIATED REACTION 21 0.0376
1 BREAKTHROUGH HAEMOLYSIS 10 0.0251
2 EXTRAVASCULAR HAEMOLYSIS 6 0.0141
3 MENINGOCOCCAL BACTERAEMIA 1 0.0104
4 PANCREATIC ENZYME ABNORMALITY 1 0.0098
5 BILIRUBINURIA 1 0.0095
6 COMPLEMENT FACTOR ABNORMAL 1 0.0093
7 SUSPECTED DRUG-INDUCED LIVER INJURY 1 0.0050
8 PURPURA FULMINANS 1 0.0039
9 MENINGOCOCCAL INFECTION 1 0.0032
See all enriched reactions for Complement C5 Inhibitor [EPC]